Barbara J. Klencke, M.D. joined our Board in September 2023. Dr. Klencke has more than 20 years of biopharmaceutical product development experience. She has served as Chief Medical Officer of ALX Oncology, Inc., a publicly traded biopharmaceutical company, on an interim basis from September 2025 and on a permanent basis since February 2026. Dr. Klencke also served on the board of directors of ALX Oncology from January to September 2025 and currently serves on the board of directors of TScan Therapeutics, Inc., a publicly traded biopharmaceutical company, which she joined in April 2023. She previously served as the Chief Medical Officer and Chief Development Officer of Sierra Oncology, Inc. (“Sierra”), a publicly traded clinical-stage biopharmaceutical company from July 2015 to June 2023, where she built a highly effective clinical development organization and led its strategy and execution, culminating in the approval of OJJAARA® for myelofibrosis after Sierra’s acquisition by GSK. While at Sierra, she concurrently served as a member of the board of directors of Lexent Bio, Inc., a publicly traded biopharmaceutical company, from May 2017 to June 2020. From 2011 to 2015, Dr. Klencke served as senior vice president of global development at Onyx Pharmaceuticals, where she led development and execution for Onyx’s pipeline programs, including the approval of KYPROLIS® for multiple myeloma, through the company’s acquisition by Amgen Inc. in 2013. Between 2003 and 2011, she served as a group medical director at Genentech, where she led product development strategies for several early- and late-stage oncology programs, including KADCYLA®, AVASTIN® and TARCEVA®. Dr. Klencke completed Internal Medicine and Hematology/Oncology training at the University of California, San Francisco and remained there as an Assistant Professor of Medicine in Oncology focusing on clinical research from 1995 to 2002. She holds a B.S. from Indiana University and an M.D. from the University of California, Davis. We believe that Dr. Klencke’s significant scientific expertise in drug development and biotechnology and her educational background qualify her to serve on our Board.